articleNatureSep 1, 2010Closed access

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

GBGideon BollagPHPeter HirthJTJames TsaiJZJiazhong ZhangPNPrabha N. Ibrahim

Universidad Estatal de Bolívar · Plex Pharmaceuticals (United States) · +11 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,821
total citations
FWCI
83.43
Percentile
100%
References
29
Citations per year

Authors

40

Topics & keywords

Topics
Keywords
  • Melanoma
  • MAPK/ERK pathway
  • Kinase
  • Cancer research
  • Medicine
  • Mutant
  • MEK inhibitor
  • Phosphorylation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.